We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04301934
Recruitment Status : Recruiting
First Posted : March 10, 2020
Last Update Posted : February 13, 2023
Information provided by (Responsible Party):
Johnny Yi, Mayo Clinic

Brief Summary:
Randomized controlled trial to determine clinical and microbiome difference between fractional CO2 Laser and vaginal estrogen in treating patients with recurrent urinary tract infection (UTI).

Condition or disease Intervention/treatment Phase
Urinary Tract Infections Device: Mona Lisa Touch Drug: Conjugated estrogen Drug: Estradiol Not Applicable

Detailed Description:

Recurrent urinary tract infection (rUTI) is common in postmenopausal women and can lead to significant bothersome symptoms. This clinical scenario is a difficult and common clinical problem seen by the urologist and urogynecologist with limited options for treatment. Overuse of antibiotics has led to significant resistant microorganisms and can have adverse side effects such as C. Dificile colitis. Current treatments include topical vaginal estrogen and prophylactic antibiotics. Other supplements such as cranberry pills, methenamine and D-mannose have varying levels of evidence and efficacy.

Fractional CO2 LASER vaginal therapy has recently been studied for the treatment of GSM. LASER therapy is currently commercially available and has FDA clearance for use in gynecology. Current evidence shows that with treatment, histologic changes of the vaginal epithelium have shown regeneration to a premenopausal state, along with subjective improvement in GSM symptoms and sexual function. Recent literature has shown improvements in thickening of vaginal epithelium, decreased vaginal pH and improvement in the vaginal microbiome. Based on this, the investigators propose fractional CO2 laser may have a positive impact on women with rUTI.

  1. The investigators therefore hypothesize that fractional CO2 LASER vaginal therapy is non-inferior to topical vaginal estrogen therapy for the treatment of rUTI.

    a. Primary Outcome: Improvement in recurrence of culture positive UTI

  2. The investigators also hypothesize that LASER therapy will improve the urinary and vaginal microbiome, decreasing the uropathogenic presence and increasing Lactobacillus.

    1. Measurement 1: The number of UTI with UPEC isolated from patients
    2. Measurement 2: The pH of the vagina as a proxy for presence of Lactobacillus sp.
    3. Measurement 3: Categorize vaginal and urinary microbial communities
  3. The investigators hypothesize that LASER therapy will improve symptoms of GSM and be associated with regenerative change in vaginal histology.

    1. Measurement 1: MESA and DIVA surveys of symptoms
    2. Measurement 2: Observations of vaginal biopsy between.

Menopausal women will be recruited if subjects have recurrent UTI defined as 3 culture positive UTIs in 1 year or 2 culture positive UTIs in 6 months. Subjects will be randomized to standard of care with topical vaginal estrogen or 3 treatments of fractional CO2 LASER of the vagina. Samples will be collected to show microbiome and histologic changes with treatment.

Samples include:

Vaginal culture Urine culture vaginal biopsy (optional).

Validated questionnaires and clinical recurrence of UTI will also be gathered over 6 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection
Actual Study Start Date : June 1, 2020
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Vaginal Estrogen Therapy Group
Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
Drug: Conjugated estrogen
Current standard treatment for recurrent UTIs in postmenopausal women
Other Name: Premarin

Drug: Estradiol
Current standard treatment for recurrent UTIs in postmenopausal women
Other Name: Estrace

Experimental: Laser Therapy Group
Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.
Device: Mona Lisa Touch
Fractional CO2 LASER

Primary Outcome Measures :
  1. Improvement in recurrence of culture positive urinary tract infections [ Time Frame: 6 months ]
    Number of culture positive, symptomatic urinary tract infections in women

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female patient >18 years old
  • Postmenopausal status, documented by prior bilateral salpingo-oophorectomy, or absence of menses >12 months
  • Recurrent urinary tract infections as defined by 3 culture positive urine cultures in the last 12 months, or 2 positive urine cultures in the last 6 months.(Positive urine cultures defined by >100K colony forming units of 1 or 2 bacterial species on clean catch sample, or >1000 colony forming units of 1 or 2 bacterial species on sample via straight catheterization).
  • Patients on vaginal estrogen must undergo a 1 month washout period prior to initiation of the trial.

Exclusion Criteria:

  • Hematuria without appropriate workup
  • Pelvic organ prolapse at or beyond the hymen
  • Clinically relevant urinary retention
  • Pelvic reconstructive surgery within 6 months
  • Prior synthetic mesh procedure for pelvic organ prolapse or urinary incontinence
  • Clinically relevant nephrolithiasis
  • History of breast cancer
  • Contraindication to topical estrogen therapy
  • Anticoagulation therapy
  • Prior pelvic or vaginal radiation therapy
  • Prior gynecologic malignancy
  • Undiagnosed genital bleeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04301934

Layout table for location information
United States, Arizona
Mayo Clinic in Arizona Recruiting
Phoenix, Arizona, United States, 85054
Contact: Arleth Valencia    480-342-6487    Valencia.Arleth@mayo.edu   
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Johnny Yi, MD Mayo Clinic
Additional Information:
Layout table for additonal information
Responsible Party: Johnny Yi, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT04301934    
Other Study ID Numbers: 18-002297
First Posted: March 10, 2020    Key Record Dates
Last Update Posted: February 13, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Urinary Tract Infections
Disease Attributes
Pathologic Processes
Urologic Diseases
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Male Urogenital Diseases
Estrogens, Conjugated (USP)
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs